ANAPTYSBIO, INC Quarterly Operating Income (Loss) in USD from Q1 2016 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Anaptysbio, Inc quarterly/annual Operating Income (Loss) history and growth rate from Q1 2016 to Q2 2024.
  • Anaptysbio, Inc Operating Income (Loss) for the quarter ending June 30, 2024 was -$40.3M, a 0.44% decline year-over-year.
  • Anaptysbio, Inc Operating Income (Loss) for the twelve months ending June 30, 2024 was -$162M, a 15.9% decline year-over-year.
  • Anaptysbio, Inc annual Operating Income (Loss) for 2023 was -$164M, a 42.8% decline from 2022.
  • Anaptysbio, Inc annual Operating Income (Loss) for 2022 was -$115M, a 103% decline from 2021.
  • Anaptysbio, Inc annual Operating Income (Loss) for 2021 was -$56.8M, a 138% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$162M -$40.3M -$178K -0.44% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-05
Q1 2024 -$162M -$42.2M +$2.2M +4.96% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$164M -$42.1M -$16.2M -62.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-11
Q3 2023 -$148M -$37.7M -$8.1M -27.3% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 -$140M -$40.1M -$12.3M -44.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 -$128M -$44.4M -$12.7M -39.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$115M -$26M +$5.18M +16.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-11
Q3 2022 -$120M -$29.6M -$22.9M -338% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$97.5M -$27.8M -$27.3M -5116% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 -$70.2M -$31.7M -$13.4M -72.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$56.8M -$31.2M -$64.5M -193% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-11
Q3 2021 $7.69M -$6.76M +$17.6M +72.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$9.89M -$533K +$22.1M +97.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$32M -$18.4M -$8.11M -79.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 -$23.9M $33.3M +$55.6M Oct 1, 2020 Dec 31, 2020 10-K 2023-03-01
Q3 2020 -$79.5M -$24.3M +$9.41M +27.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$88.9M -$22.6M +$4.02M +15.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$92.9M -$10.3M +$14.5M +58.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 -$107M -$22.3M -$2.6M -13.2% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-02
Q3 2019 -$105M -$33.7M -$16.9M -99.8% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 -$88M -$26.7M -$12.2M -84.9% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 -$75.7M -$24.8M -$9.02M -57.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q4 2018 -$66.7M -$19.7M -$12.5M -175% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-02
Q3 2018 -$54.2M -$16.9M -$7.8M -85.8% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-02
Q2 2018 -$46.4M -$14.4M -$11.9M -464% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-02
Q1 2018 -$34.6M -$15.8M -$5.77M -57.8% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-02
Q4 2017 -$28.8M -$7.15M -$3.98M -125% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 -$24.8M -$9.09M -$8.01M -745% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 -$16.8M -$2.56M -$4.92M -208% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 -$11.9M -$9.99M -$8.85M -777% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
Q4 2016 -$3.03M -$3.17M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-05
Q3 2016 -$1.08M Jul 1, 2016 Sep 30, 2016 10-K 2018-03-05
Q2 2016 $2.36M Apr 1, 2016 Jun 30, 2016 10-K 2018-03-05
Q1 2016 -$1.14M Jan 1, 2016 Mar 31, 2016 10-K 2018-03-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.